secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001104659-25-026130
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem updates pipeline; PDUFA June 30, 2025 for avutometinib+defactinib in LGSOC
--------------------------------------------------------------------------------

- PDUFA action date June 30, 2025 for NDA of avutometinib+defactinib in KRAS mutant recurrent LGSOC; launch prep underway.
- RAMP 201 data: 44% ORR in KRAS mt, 31% overall; median PFS 12.9 months; 82% of patients had tumor shrinkage.
- Confirmatory RAMP 301 Phase 3 enrollment on track for completion by end of 2025.
- Filed U.S. IND for VS-7375 (KRAS G12D inhibitor) in Q1 2025; Phase 1/2a initiation expected mid-2025.
- Plan to present RAMP 203 (NSCLC) and RAMP 205 (pancreatic) data at med meetings in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/0001104659-25-026130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer